Malaga Cove Capital LLC Raises Holdings in Pacira Pharmaceuticals, Inc. (PCRX)
Malaga Cove Capital LLC raised its stake in shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) by 166.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 20,609 shares of the company’s stock after buying an additional 12,877 shares during the period. Malaga Cove Capital LLC owned about 0.05% of Pacira Pharmaceuticals worth $777,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of PCRX. Oppenheimer Asset Management Inc. acquired a new stake in shares of Pacira Pharmaceuticals during the 2nd quarter valued at $114,000. Benjamin F. Edwards & Company Inc. boosted its stake in shares of Pacira Pharmaceuticals by 12.2% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 2,794 shares of the company’s stock valued at $133,000 after buying an additional 303 shares during the period. Cubist Systematic Strategies LLC lifted its stake in shares of Pacira Pharmaceuticals by 121.5% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock valued at $152,000 after purchasing an additional 1,752 shares during the last quarter. QS Investors LLC acquired a new stake in shares of Pacira Pharmaceuticals in the 2nd quarter valued at $157,000. Finally, Ameritas Investment Partners Inc. lifted its stake in shares of Pacira Pharmaceuticals by 9.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock valued at $165,000 after purchasing an additional 302 shares during the last quarter. 99.79% of the stock is owned by institutional investors.
Shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) traded up $0.75 on Monday, reaching $40.25. 715,900 shares of the company traded hands, compared to its average volume of 843,788. Pacira Pharmaceuticals, Inc. has a 12-month low of $29.81 and a 12-month high of $58.95. The company has a current ratio of 6.99, a quick ratio of 6.24 and a debt-to-equity ratio of 1.03.
Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings data on Wednesday, November 8th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The company had revenue of $67.30 million for the quarter, compared to the consensus estimate of $68.99 million. During the same quarter in the previous year, the firm posted $0.20 EPS. The business’s revenue was down 1.6% compared to the same quarter last year. research analysts expect that Pacira Pharmaceuticals, Inc. will post -0.87 EPS for the current fiscal year.
Several research firms recently issued reports on PCRX. BMO Capital Markets reduced their price objective on shares of Pacira Pharmaceuticals from $42.00 to $40.00 and set a “market perform” rating for the company in a research note on Thursday, August 3rd. Wedbush reaffirmed an “outperform” rating and issued a $87.00 price objective (up previously from $80.00) on shares of Pacira Pharmaceuticals in a research note on Monday. Canaccord Genuity reaffirmed a “buy” rating and issued a $56.00 price objective on shares of Pacira Pharmaceuticals in a research note on Monday, July 31st. HC Wainwright set a $59.00 price objective on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. Finally, ValuEngine lowered shares of Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $49.71.
In related news, Director Mark A. Kronenfeld acquired 1,000 shares of the company’s stock in a transaction dated Friday, November 10th. The shares were bought at an average price of $41.60 per share, for a total transaction of $41,600.00. Following the acquisition, the director now owns 6,795 shares in the company, valued at approximately $282,672. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO David M. Stack sold 58,885 shares of the business’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $38.34, for a total transaction of $2,257,650.90. Following the transaction, the chief executive officer now owns 159,164 shares in the company, valued at approximately $6,102,347.76. The disclosure for this sale can be found here. Insiders own 6.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/11/20/malaga-cove-capital-llc-raises-holdings-in-pacira-pharmaceuticals-inc-pcrx.html.
Pacira Pharmaceuticals Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Stock Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.